Search

Leukotriene D4

Leukotriene D4 has been used in trials studying the diagnostic of Asthma and Allergic Rhinitis.

Pegaspargase

[A255912,A255917] In February 1994, pegaspargase was approved by the FDA for the treatment of ALL in patients with hypersensitivity to native forms of L-asparaginase.[A255927] … Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia

Bermekimab

Bermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).

CH-1504 L-isomer

CH-1504 L-isomer is under investigation in clinical trial NCT01116141 (A Study of CH-4051 in Patients With Rheumatoid Arthritis (RA)).

Selinexor

[L10145] The FDA approved Selinexor in June 2019. … Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound.

Tocotrienol

Tocotrienol has been investigated for the treatment of Cholesterol Lowering.

Deucravacitinib

Deucravacitinib is a novel oral selective tyrosine kinase 2 (TYK2) inhibitor. … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.

Penpulimab

Penpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … [A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998]

Atacicept

factor (BAFF) and A Proliferation Inducing Ligand (APRIL). … Atacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating

Montmorillonite